Gary W. Herschman and Anjana D. Patel, Members of the Firm in the Health Care & Life Sciences practice, in the firm’s Newark office, co-authored an article in Ophthalmology Management, titled “Private Equity in the COVID Era: A Look at the Private Equity Landscape in Ophthalmology.”

Following is an excerpt:

It’s no secret that private equity (PE) investment in ophthalmology and other medical specialties has been on the rise over the last several years. The number of PE transactions in ophthalmology and eye-care practices have been robust recently, and have snowballed to more than 20 transac­tions in the first quarter of 2020 alone, according to Bloomberg Law ( But that was before the COVID-19 pandemic hit and transaction activity ground almost to a halt.

Now that our economy is beginning to recover, let’s take another look at the PE landscape.

Transaction Activity: Pre-Covid-19 and Now

We say “ground almost to a halt,” because some of these transactions that were well underway when the pandemic hit the United States earlier this year were initially put on pause but eventu­ally closed a few months later. Others, especially those deals in the nascent stages, were put on a longer hold while PE and their lenders assessed the risks and uncertainty facing certain special­ties, such as ophthalmology, and whether those specialties would soon be able to open for busi­ness as usual. Complicating factors such as the patchwork nationwide response to the pandemic and geographic variances of the impact of the pandemic made this assessment more difficult.

In the last couple of months, however, our research shows that transaction activity has picked up with over a dozen eye-care transac­tions in the third quarter. Whether this activity will return to the pre-COVID pace remains to be seen. However, as PE investors and their lenders get more comfortable with the COVID economic environment, we expect more eye-care deals to close in the next 3 to 6 months and beyond.


Some of the fall-out from the pandemic has been a renewed look at how to value physician deals. Current deal valuations may be lower because many of these deals are valued at physician group’s EBITDA, and COVID has impacted that cash flow. Some investors, however, are basing valuations on 2019 financial results — as long as there is proof that the groups have returned to, or are close to returning to, pre-COVID levels.

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.